Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Top Cited Papers
Open Access
- 6 November 2023
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (3) , 360-371
Abstract
Objectives To evaluate the safety and efficacy of remibrutinib in patients with moderate-to-severe Sjögren’s syndrome (SjS) in a phase 2 randomised, double-blind trial (NCT04035668; LOUiSSE (LOU064 in Sjögren’s Syndrome) study). Methods Eligible patients fulfilling 2016 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for SjS, positive for anti-Ro/Sjögren’s syndrome-related antigen A antibodies, with moderate-to-severe disease activity (EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (based on weighted score) ≥ 5, EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) ≥ 5) received remibrutinib (100 mg) either one or two times a day, or placebo for the 24-week study treatment period. The primary endpoint was change from baseline in ESSDAI at week 24. Key secondary endpoints included change from baseline in ESSDAI over time, change from baseline in ESSPRI over time and safety of remibrutinib in SjS. Key exploratory endpoints included changes to the salivary flow rate, soluble biomarkers, blood transcriptomic and serum proteomic profiles. Results Remibrutinib significantly improved ESSDAI score in patients with SjS over 24 weeks compared with placebo (ΔESSDAI −2.86, p=0.003). No treatment effect was observed in ESSPRI score (ΔESSPRI 0.17, p=0.663). There was a trend towards improvement of unstimulated salivary flow with remibrutinib compared with placebo over 24 weeks. Remibrutinib had a favourable safety profile in patients with SjS over 24 weeks. Remibrutinib induced significant changes in gene expression in blood, and serum protein abundance compared with placebo. Conclusions These data show preliminary efficacy and favourable safety of remibrutinib in a phase 2 trial for SjS.Keywords
Funding Information
- Novartis
This publication has 38 references indexed in Scilit:
- Fc Receptor–like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue–like Memory B CellsThe Journal of Immunology, 2016
- Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2015
- Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II studyRheumatology, 2015
- Large-scale serum protein biomarker discovery in Duchenne muscular dystrophyProceedings of the National Academy of Sciences, 2015
- Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II studyAnnals of the Rheumatic Diseases, 2015
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- The epidemiology of Sjögren’s syndromeClinical Epidemiology, 2014
- Clock Genes Show Circadian Rhythms in Salivary GlandsJournal of Dental Research, 2012
- Sjögren's syndromeThe Lancet, 2005
- Btk function in B cell development and responseSeminars in Immunology, 1998